DS specifically binds to LRP1, disrupts lysosomal function, and activates TBK1-dependent IFN-I signaling, thereby reprogramming the TME and enhancing the tumor’s response to anti-PD-1 or STING agonist treatment. The gene discussed is LRP1; the disease is neoplasm.